The Insight Partners Latest Research on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028″ Focuses COVID-19 Impact and Global Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)
“Non-Alcoholic Steatohepatitis (NASH) Market is expected to grow from US$ 1,631.92 million in 2021 to US$ 24,266.81 million by 2028; it is estimated to grow at a CAGR of 47.1% from 2021 to 2028. The report highlights the major factors driving the market, and prominent players and their developments in the market. The growth of the non-alcoholic steatohepatitis (NASH) market is mainly driven by the rising prevalence of NASH and increasing initiatives for the awareness of NASH. However, the lack of established guidelines for the diagnosis and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the market growth.
Download PDF Sample Copy at: https://www.theinsightpartners.com/sample/TIPRE00009653/
Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are types of NAFLD. Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Growth of the global nonalcoholic steatohepatitis (NASH) market is majorly driven by rising prevalence of NASH and increasing initiatives for the awareness of NASH. However, lack of established guidelines in the diagnosis and withdrawal of drugs from seeking marketing authorization for NASH is hampering market growth.
Leading Companies Outlook:
The Non-alcoholic steatohepatitis (NASH) market is majorly comprised of top players involving Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the Non-alcoholic steatohepatitis (NASH) market:
Mar-2022: Novartis announced that it has signed agreement with Carisma Therapeuticsto manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
Apr-2022: Sandoz announced its extension of collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR)
Jan-2022: Galmed Pharmaceuticals Ltd. announced that the United States Patent and Trademark Office (USPTO) granted Galmed new patents related to the use of Aramchol for the treatment of fibrosis and for the treatment for modulating gut microbiota
Ask for Discount at: https://www.theinsightpartners.com/discount/TIPRE00009653/
The report segments the non-alcoholic steatohepatitis (NASH) market as follows:
The non-alcoholic steatohepatitis (NASH) market is segmented on the basis of product, application, sales channel and geography.
Based on product, the market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others.
Based on application, the non-alcoholic steatohepatitis (NASH) market is bifurcated into treatment and diagnosis.
Based on sales channel, the non-alcoholic steatohepatitis (NASH) market is segmented into hospital pharmacy, retail pharmacy, and online provider.
By geography, the non-alcoholic steatohepatitis (NASH) market is segmented as North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. ~25% of adults in the US have been estimated to have NAFLD, of which ~20% have NASH, i.e., 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% from 2015 to 2030 and NASH is predicted to become the major cause of liver transplantation in the US during 2020–2025. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease till 2030. As per the study, the prevalence of NAFLD and NASH cases is expected to increase by 21% and 63%, respectively, resulting in 33.5% and 27% prevalence rates, respectively, in adults.
Buy Report at: https://www.theinsightpartners.com/buy/TIPRE00009653/
About The Insight Partners:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi